HELP (HELP) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving HELP (HELP) right now is Phase 3 depression readout: The PARADIGM program (APPROACH plus EMBRACE) testing HLP003 in major depressive disorder is the central catalyst, with topline data anticipated around Q4 2026. Revenue (TTM) is ~$0 (pre-revenue, under $1M). If that keeps playing out, the setup is favourable; the risk to it is as a clinical-stage company, Cybin has negligible revenue and posts ongoing net losses, so it depends on trial success and repeated financing to survive. No one can predict where HELP trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive HELP (HELP) higher?
1. Phase 3 depression readout
The PARADIGM program (APPROACH plus EMBRACE) testing HLP003 in major depressive disorder is the central catalyst, with topline data anticipated around Q4 2026. A clean efficacy and safety result would be the most material value driver, since MDD is a large addressable market and few psychedelic therapies have reached pivotal-stage data.
2. Anxiety program optionality
HLP004, a deuterated DMT compound, is in Phase 2 for generalized anxiety disorder with an earlier data readout expected around Q1 2026. Positive signals here would broaden the pipeline beyond a single depression bet and give the platform a second indication.
3. Cash position and financing
Cybin ended 2025 with roughly $195 million in cash, which funds its late-stage trials but implies continued reliance on capital markets. The pace of spending versus milestone timing shapes how much additional dilution shareholders may face before any potential approval.
4. Psychedelic-medicine regulatory path
The broader environment for FDA review of psychedelic and serotonergic therapies is still developing. Clearer agency guidance and precedent from peers could de-risk the category, while setbacks at competing programs could weigh on sentiment across the space.
What could weigh on HELP?
As a clinical-stage company, Cybin has negligible revenue and posts ongoing net losses, so it depends on trial success and repeated financing to survive. A Phase 3 miss, ambiguous data, or safety signal for HLP003 would be highly damaging given the concentration in a single lead program. Equity raises have diluted existing holders and are likely to continue until the company reaches profitability, which is not forecast in the near term. Regulatory uncertainty around psychedelic therapies, the operational complexity of supervised administration, and competition from other developers add further risk. The stock is volatile and can move sharply on single data points.
Where HELP trades today
A forecast starts from where the stock actually is. These are HELP's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for HELP as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a HELP forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the HELP guide and whether HELP is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the HELP outlook
The bottom line: what is driving HELP (HELP) is Phase 3 depression readout, with revenue (ttm) at ~$0 (pre-revenue, under $1M). If that keeps playing out the setup is favourable; the risk is as a clinical-stage company, Cybin has negligible revenue and posts ongoing net losses, so it depends on trial success and repeated financing to survive. No one can predict the price, so treat any HELP forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around HELP with Walnut
Use HELP as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for HELP (HELP)?
+
No one can reliably predict where HELP will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push HELP higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive HELP higher?
+
The main growth drivers are Phase 3 depression readout; Anxiety program optionality; Cash position and financing. Whether they play out is the real question, not a guaranteed path.
What are the risks to HELP?
+
As a clinical-stage company, Cybin has negligible revenue and posts ongoing net losses, so it depends on trial success and repeated financing to survive. A Phase 3 miss, ambiguous data, or safety signal for HLP003 would be highly damaging given the concentration in a single lead program. Equity raises have diluted existing holders and are likely to continue until the company reaches profitability, which is not forecast in the near term. Regulatory uncertainty around psychedelic therapies, the operational complexity of supervised administration, and competition from other developers add further risk. The stock is volatile and can move sharply on single data points.
Will HELP stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. HELP's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is HELP a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the HELP "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.